0K2H Stock Overview
A clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Moleculin Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$5.36 |
| 52 Week Low | US$0.42 |
| Beta | 2.2 |
| 1 Month Change | 17.71% |
| 3 Month Change | -33.88% |
| 1 Year Change | -81.05% |
| 3 Year Change | -95.38% |
| 5 Year Change | -99.32% |
| Change since IPO | -99.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K2H | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.3% | 13.1% | 2.1% |
| 1Y | -81.0% | -13.9% | 2.2% |
Return vs Industry: 0K2H underperformed the UK Biotechs industry which returned -13.9% over the past year.
Return vs Market: 0K2H underperformed the UK Market which returned 2.2% over the past year.
Price Volatility
| 0K2H volatility | |
|---|---|
| 0K2H Average Weekly Movement | 101.5% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0K2H's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0K2H's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 17 | Wally Klemp | moleculin.com |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
Moleculin Biotech, Inc. Fundamentals Summary
| 0K2H fundamental statistics | |
|---|---|
| Market cap | US$14.42m |
| Earnings (TTM) | -US$21.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 0K2H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K2H income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.76m |
| Earnings | -US$21.76m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0K2H perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 22:24 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moleculin Biotech, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vernon Bernardino | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |